5 Alpha Reductase Inhibitors (5ARIs) Monotherapy and Combinations: Current Role in Benign Prostatic Hyperplasia (BPH) Management
Medicina · 17.05.2026 · 62 (5) · 975
DOI: 10.3390/medicina62050975 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medicina, online erschienen am 17.05.2026. Verfasst von Christos Roidos und 4 weiteren Autor:innen. Beteiligte Einrichtung: 1st Department of Urology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, 541 24 Thessaloniki, Greece. Hauptthemen laut MEDLINE: Prostatic Hyperplasia, 5-alpha Reductase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and Objectives: Benign prostatic hyperplasia (BPH) is a progressive, androgen-dependent condition driven by dihydrotestosterone (DHT). 5α-reductase inhibitors (5-ARIs), including finasteride and dutasteride, target this pathway and provide disease-modifying effects. Materials and Methods: This narrative review summarizes evidence from randomized trials, meta-analyses, and observational studies evaluating the efficacy, timing, and safety of 5-ARIs in the management of LUTS due to BPH.
Results
5-ARI therapy reduces prostate volume by 18–28% and serum PSA by approximately 50% within 6–12 months. Landmark trials (MTOPS, CombAT) demonstrate significant reductions in acute urinary retention (AUR) and BPH-related surgery (>50% RR reduction). Combination therapy with α-blockers provides superior symptom control and greater prevention of clinical progression, particularly in men with prostate volume ≥ 30–40 mL or PSA ≥ 1.5 ng/mL. Early initiation of combination therapy improves long-term outcomes, while α-blocker withdrawal may be feasible in selected patients. Adverse events are mainly sexual, with emerging data suggesting a possible association with depression.
Conclusions
5-ARIs are central to BPH management, offering sustained clinical benefits and prevention of progression. Optimal outcomes depend on appropriate patient selection, early treatment in high-risk individuals, and individualized long-term strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- 1st Department of Urology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, 541 24 Thessaloniki, Greece.
ORCID-Profile: Christos Roidos, Petros Sountoulides, Asterios Symeonidis
Zitieren
APA
Roidos, C., Sountoulides, P., Papathanasiou, K., Symeonidis, A., & Mykoniatis, I. (2026). 5 Alpha Reductase Inhibitors (5ARIs) Monotherapy and Combinations: Current Role in Benign Prostatic Hyperplasia (BPH) Management. Medicina, 62(5), 975. https://doi.org/10.3390/medicina62050975
Vancouver
Roidos C, Sountoulides P, Papathanasiou K, Symeonidis A, Mykoniatis I. 5 Alpha Reductase Inhibitors (5ARIs) Monotherapy and Combinations: Current Role in Benign Prostatic Hyperplasia (BPH) Management. Medicina. 2026;62(5):975. doi:10.3390/medicina62050975
BibTeX
@article{Roidos2026,
author = {Roidos, Christos and Sountoulides, Petros and Papathanasiou, Konstantinos and Symeonidis, Asterios and Mykoniatis, Ioannis},
title = {5 Alpha Reductase Inhibitors (5ARIs) Monotherapy and Combinations: Current Role in Benign Prostatic Hyperplasia (BPH) Management},
journal = {Medicina},
year = {2026},
volume = {62},
number = {5},
pages = {975},
doi = {10.3390/medicina62050975}
}
EUVIMED